Researchers at the University of Louisville School of Medicine are using breath analysis to detect the presence of lung cancer.
Preliminary data indicate that this promising noninvasive tool offers the sensitivity of PET scanning, and has almost twice the specificity of PET for distinguishing patients with benign lung disease from those with early stage cancer. Michael Bousamra II, MD, Associate Professor, Department of Cardiovascular and Thoracic Surgery, is presenting the results of the study at the AATS 2014 Conference on April 29, 2014.
A reliable, noninvasive diagnostic method imposes less physical and financial burden on patients who actually have no significant disease, while rapid and accurate diagnosis expedites treatment for patients who truly have lung cancer.
The team believes that while the breath test would not replace CT as a primary screening tool, it would be particularly helpful in conjunction with a positive CT scan result. “This breath analysis method presents the potential for a cheaper and more reliable diagnostic option for patients found to have bulky disease on a CT scan. If the breath analysis is negative, the patient may, in some instances, be followed with repeated exams without necessitating a biopsy. But a positive breath analysis would indicate that the patient may proceed to definitive biopsy, thus expediting treatment,” says Dr. Bousamra.
Investigators used specially coated silicon microchips to collect breath samples from 88 healthy controls, 107 patients with lung cancer, 40 individuals with benign pulmonary disease, and 7 with metastatic lung cancer.
Previous work had pinpointed four specific substances, known as carbonyl compounds, in breath samples as “elevated cancer markers” (ECMs) that distinguish patients with lung cancer from those with benign disease. The carbonyl compounds found in the breath are thought to reflect chemical reactions occurring in malignant lung tumors. In this study, the authors compared the findings from the breath analyses to the results from PET scans.
The investigators found that the sensitivity and specificity of breath analysis depended upon how many of the ECMs were elevated. For example, having 3 or 4 ECMs was diagnostic of lung cancer in 95% of those with this result. The majority of patients with benign pulmonary disease had either 0 or 1 ECM, while those with Stage IV cancer were most likely to have 3 or 4. The number of ECMs could be used to differentiate benign disease from both early and advanced stage lung cancer. Interestingly, 3 of the 4 elevated markers returned to normal levels after cancer resection.
When it comes to differentiating early stage lung cancer from benign pulmonary disease, breath analysis and PET scanning had similar sensitivities (82.8% and 90.3%, respectively). However, breath analysis had a much higher specificity than PET (75% vs. 38.7%, respectively) for distinguishing benign disease, which means that it was much more accurate at identifying those who did not have cancer. This would be an important feature for patients with benign disease, since having a breath analysis rather than PET scan could mean avoiding an unnecessary invasive biopsy procedure later on.
The Latest on: Detect Early Lung Cancer
[google_news title=”” keyword=”Detect Early Lung Cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Detect Early Lung Cancer
- Lima Memorial Partners with Eon for AI-Powered Early Cancer Detection Programon May 9, 2024 at 8:18 am
Lima Memorial Health System has joined forces with Eon, a leading healthtech company dedicated to revolutionizing the way incidental findings ...
- Lung Cancer Is The Deadliest, Screening Could Save Many Liveson May 9, 2024 at 7:30 am
Lung cancer screening can save lives, but it isn’t accessible to everyone at risk of developing the disease ...
- Welcome to Las Vegas Sign lights up for 65th anniversary and Lung Cancer Action Weekon May 8, 2024 at 6:13 pm
The iconic 'Welcome to Fabulous Las Vegas sign' is lighting up to celebrate multiple achievements across the valley.
- Understanding IP Matters: How AI and IP Are Making a Difference in Early Cancer Detectionon May 8, 2024 at 5:15 am
Huge datasets and limitless computing power are converging to upend the practice of healthcare, especially the speed and accuracy of detecting major diseases. Alan C. Nelson discusses this and more ...
- Lung cancer is the deadliest of all cancers, and screening could save many lives − if more people could access iton May 7, 2024 at 5:33 am
Many medical organizations have been recommending lung cancer screening for decades for those at high risk of developing the disease. But in 2022, less than 6% of people in the U.S. eligible for ...
- Lung Cancer Action Week helping to raise awareness of a deadly diseaseon May 6, 2024 at 5:49 pm
Lung cancer was recognized across the nation the week of May 6, 2024. Lung Cancer Action Week is a time to support and acknowledge the fight against lung cancer The American Cancer Society says that ...
- Transforming lung cancer detectionon May 3, 2024 at 2:56 am
Mortality rates are so high because the disease is notoriously difficult to detect in its early stages, causing no to very mild symptoms to be presented by patients. As a result, most people are not ...
- Hartford Healthcare: Lung cancer leading cause of cancer-related deathson May 2, 2024 at 10:13 am
Lung cancer is the leading cause of cancer-related deaths in the United States. Next week, “Lung Cancer Action Week” is an important time to raise awareness about ...
- contextflow targets early lung cancer detection by augmenting ADVANCE Chest CT with malignancy scoring from RevealDXon May 2, 2024 at 1:32 am
In addition to lung nodule detection, quantification, visualization and classification, the updated software now analyzes nodules for malignancy with the aim of detecting cancer early and reducing ...
- More Resources Needed to Detect Cancer Earlieron April 30, 2024 at 5:00 pm
And lung cancer is the number one killer ... And only 600, 9% is spent on early detection. It should be exactly reversed. If we're talking about therapeutics here and we're talking about early ...
via Bing News